API Formulation

Less than 1 min 06/05/21
Author name: John Ross

Formulating with highly insoluble, crystalline APIs

Many new compounds and chemistries have either low solubility, low bioavailability, or both. In a recent issue of Solid Dose Digest’s “Ask an Expert,” Dr. Yogesh Sadhale, Director of Pharmaceutical DevelopmeIn a recent issue of Solid Dose Digest’s “Ask an Expert,” Dr. Yogesh Sadhale, Director of Pharmaceutical Development at Metrics, explains the formulation options available for highly insoluble, crystalline APIs.nt at Metrics, explains the formulation options available for highly insoluble, crystalline APIs. “Many highly potent active pharmaceutical ingredients (APIs) available today are crystalline in nature and exhibit poor solubility. In addition, payers and sponsors also insist on simplified, patient-centric, once daily (OD) dosing regimens to boost dose compliance and therapeutic performance.” Read the full article here.


Related Content